PDCD1 and neoplasm: Collectively, these results provided abundant evidences that Iacs-miR-30C treatment allowed overcoming T cell exclusion and amplified anti-tumor effects in anti-PD-1 antibody therapy through suppressing Wnt signaling cascade.